Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Ultane Pen Btl Liquid 250 Ml By Abbvie Us.

Image 0 of Ultane Pen Btl Liquid 250 Ml By Abbvie Us. Image 1 of Ultane Pen Btl Liquid 250 Ml By Abbvie Us.

Ultane Pen Btl Liquid 250 Ml By Abbvie Us.

Call for Price

Ultane Pen Btl Liquid 250 Ml By Abbvie Us. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD2998813/RXB10018018
Size : 250 ML
Selling UoM : EA
NDC: 00074-4456-04
UPC Barcode : 300744456041
Supplier: 0050001088 ABBVIE US LLC
Supplier Material : 044560405
Generic Code : 023743 SEVOFLURANE INHALATION LIQUID
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Call for Price

Product Description.:

Liquid , clear , clear

ULTANE? (sevoflurane) is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of ULTANE should be used.

ULTANE can cause malignant hyperthermia. ULTANE is contraindicated in patients with known sensitivity to any of its product ingredients, or to other halogenated agents, or in patients with known or suspected susceptibility to malignant hyperthermia. Use of ULTANE for more than 2-MAC hours at flow rates of 1 to <2 L/min may be associated with a potential for renal injury, glycosuria, and proteinuria. Fresh gas flow rates <1 L/min are not recommended. KOH containing CO2 absorbents are not recommended for use with ULTANE. Patients may develop perioperative hyperkalemia, excessive decreases in blood pressure, respiratory depression, seizures, and postoperative hepatic dysfunction or hepatitis with or without jaundice.

Indication and Important Safety Information you should know about Ultane? (sevoflurane)

Indication1

* ULTANE? (sevoflurane) is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of ULTANE should be used.

Important Safety Information1

* Sevoflurane can cause malignant hyperthermia. ULTANE should not be used in patients with known sensitivity to sevoflurane, or to other halogenated agents, or in patients with known or suspected susceptibility to malignant hyperthermia.
* Findings taken from patient and animal studies suggest that there is a potential for renal injury when ULTANE is used at low flow rates, which is presumed due to Compound A. The level of Compound A exposure at which clinical nephrotoxicity might be expected to occur has not been established. To minimize exposure to Compound A, ULTANE exposure should not exceed 2 MAC-hours at flow rates of 1 to <2 L/min. Fresh gas flow rates <1 L/min are not recommended.
* Because clinical experience in administering ULTANE to patients with renal insufficiency (creatinine >1.5 mg/dL) is limited, its safety in these patients has not been established.
* ULTANE may be associated with glycosuria and proteinuria when used for long procedures at low flow rates.
* KOH containing CO2 absorbents are not recommended for use with ULTANE. An exothermic reaction occurs when ULTANE is exposed to CO2 absorbents. This reaction is increased when the CO2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters. Rare cases of extreme heat, smoke, and/or spontaneous fire in the anesthesia breathing circuit have been reported during ULTANE use in conjunction with the use of desiccated CO2 absorbent, specifically those containing potassium hydroxide (e.g. Baralyme). Replace CO2 absorbents routinely regardless of the state of the color indicator.
* Rare increases in serum potassium resulting in cardiac arrhythmias and death have been noted in pediatric patients during the postoperative period following the use of inhaled anesthetic agents. Contributing risk factors appear to be latent or overt neuromuscular disease, particularly Duchenne muscular dystrophy. Concomitant use of succinylcholine has been associated with most, but not all of these cases. Early, aggressive intervention to treat both hyperkalemia and resistant arrhythmias, and subsequent evaluation for latent neuromuscular disease, is recommended.
* Due to ULTANE?s insolubility in blood, hemodynamic changes may occur more rapidly than with other volatile anesthetics. Excessive decreases in blood pressure or respiratory depression may be related to depth of anesthesia and may be corrected by decreasing the inspired concentration of ULTANE.
* Seizures have been reported in association with ULTANE use, the majority of which have occurred in children and young adults, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using ULTANE in patients who may be at risk for seizures.
* Drug Interactions: Benzodiazepines and opioids would be expected to decrease the MAC of ULTANE. The anesthetic requirement for ULTANE is decreas